Under construction – not a live service
Sign in

NCT06045065Completed

Preclinical Brain Tumor Models

HITCH · Run by Assistance Publique Hopitaux De Marseille

Establishment of Pre-clinical Stem Line and Tumoroid Models of Brain Tumors

Source: ClinicalTrials.gov · Last updated 5 Nov 2026

Next steps

Brief summary (registry, in English)

Background: Primary or secondary brain tumors (metastases) remain associated with a very poor prognosis linked to significant therapeutic resistance. Thus, glioblastoma, which is the most common and aggressive primary brain tumor in adults, is associated with inevitable relapses within 7 to 10 months and median survival of approximately 12 to 14 months. At the same time, brain metastases are increasingly increasing following better systemic control of other metastatic sites and improvement in detection methods. However, they remain resistant to the latest therapeutic innovations such as immunotherapies or targeted therapies. In this context, innovative strategies are necessary to identify new therapeutic targets and implement new treatments to overcome resistance phenomena in the clinic. Objective: Our goal will be to generate tumoroids and stem-like cell lines (PDX) from patient tumor samples. Methods: We will establish tumor tumoroids and stem cell lines from patient samples. These preclinical models will allow us to test a large number of drugs, quickly and efficiently thanks to models as close as possible to patient tumors and limiting the use of animal models (3R). Overall, this project should enable major advances in the treatment of glioblastoma and brain metastases and enable the rapid testing of new molecules in clinical trials thanks to the homology of our models with our patients' diseases.

Status (registry)
Completed
Study type
Observational
Enrollment
60 (actual)
First submitted
13 Sept 2023
Start date
2 Jan 2022
Primary completion date
25 Nov 2024
Lead sponsor
Assistance Publique Hopitaux De Marseille
Diseases
Glioblastoma
NCT number
NCT06045065

What you commit to

  • Study type: Observational
  • Participants enrolled: 60
  • From 2 Jan 2022 to the primary completion date, 25 Nov 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study design.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • unresectable tumor

Who the study is looking for

  • Adult patients
  • Brain tumor neuro-imaging
  • Eligible for neurosurgery

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Assistance Publique Hôpitaux de MarseilleMarseilleFranceUnknown status

Are you the coordinator? Confirm the details

The registry text, word for word

This page is information, not medical advice. Discuss any trial with your doctor.